NEWTONE PHARMA LIMITED

Company Registration Number:
08556296 (England and Wales)

Unaudited statutory accounts for the year ended 30 June 2024

Period of accounts

Start date: 1 July 2023

End date: 30 June 2024

NEWTONE PHARMA LIMITED

Contents of the Financial Statements

for the Period Ended 30 June 2024

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes

NEWTONE PHARMA LIMITED

Directors' report period ended 30 June 2024

The directors present their report with the financial statements of the company for the period ended 30 June 2024

Principal activities of the company

Wholesale of sugar and chocolate and sugar confectionery. Wholesale of pharmaceutical goods. Non-specialised wholesale trade.



Directors

The director shown below has held office during the whole of the period from
1 July 2023 to 30 June 2024

Chrysovalentine GARRETT


The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
3 March 2025

And signed on behalf of the board by:
Name: Chrysovalentine GARRETT
Status: Director

NEWTONE PHARMA LIMITED

Profit And Loss Account

for the Period Ended 30 June 2024

2024 2023


£

£
Turnover: 1,014,584 1,398,323
Cost of sales: ( 970,481 ) ( 983,717 )
Gross profit(or loss): 44,103 414,606
Administrative expenses: ( 1,774 ) ( 1,890 )
Operating profit(or loss): 42,329 412,716
Profit(or loss) before tax: 42,329 412,716
Tax: ( 8,043 ) ( 7,590 )
Profit(or loss) for the financial year: 34,286 405,126

NEWTONE PHARMA LIMITED

Balance sheet

As at 30 June 2024

Notes 2024 2023


£

£
Fixed assets
Investments: 3 59,246 59,246
Total fixed assets: 59,246 59,246
Current assets
Cash at bank and in hand: 17,689 50,359
Total current assets: 17,689 50,359
Creditors: amounts falling due within one year: 4 ( 8,043 ) ( 7,590 )
Net current assets (liabilities): 9,646 42,769
Total assets less current liabilities: 68,892 102,015
Creditors: amounts falling due after more than one year: 5 ( 275,813 ) ( 350,813 )
Total net assets (liabilities): (206,921) (248,798)
Capital and reserves
Called up share capital: 1,000 1,000
Profit and loss account: (207,921 ) (249,798 )
Total Shareholders' funds: ( 206,921 ) (248,798)

The notes form part of these financial statements

NEWTONE PHARMA LIMITED

Balance sheet statements

For the year ending 30 June 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 3 March 2025
and signed on behalf of the board by:

Name: Chrysovalentine GARRETT
Status: Director

The notes form part of these financial statements

NEWTONE PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2024

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

    Turnover policy

    Turnover represents the invoiced value of goods and services supplied by the company, net of value added tax and trade discounts

NEWTONE PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2024

  • 2. Employees

    2024 2023
    Average number of employees during the period 0 1

NEWTONE PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2024

3. Fixed assets investments note

Investments

NEWTONE PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2024

4. Creditors: amounts falling due within one year note

2024 2023
£ £
Taxation and social security 8,043 7,590
Total 8,043 7,590

NEWTONE PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 30 June 2024

5. Creditors: amounts falling due after more than one year note

2024 2023
£ £
Other creditors 275,813 350,813
Total 275,813 350,813